Athira Pharma, Inc. (NASDAQ:ATHA – Get Free Report) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 1,100,000 shares, a growth of 8.9% from the June 15th total of 1,010,000 shares. Based on an average daily volume of 157,000 shares, the days-to-cover ratio is currently 7.0 days. Currently, 3.1% of the shares of the stock are sold short.
Athira Pharma Stock Performance
NASDAQ:ATHA opened at $3.40 on Thursday. The company has a market cap of $130.32 million, a price-to-earnings ratio of -1.11 and a beta of 2.90. The stock’s fifty day moving average price is $2.62 and its two-hundred day moving average price is $2.78. Athira Pharma has a 52-week low of $1.33 and a 52-week high of $4.30.
Athira Pharma (NASDAQ:ATHA – Get Free Report) last released its earnings results on Wednesday, May 15th. The company reported ($0.69) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.11. On average, equities analysts predict that Athira Pharma will post -2.79 EPS for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Analysis on Athira Pharma
Insider Buying and Selling
In other news, Director Kelly A. Romano acquired 15,000 shares of the company’s stock in a transaction dated Friday, June 21st. The stock was bought at an average price of $2.26 per share, with a total value of $33,900.00. Following the completion of the acquisition, the director now owns 53,315 shares in the company, valued at approximately $120,491.90. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Athira Pharma news, Director Kelly A. Romano purchased 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 21st. The stock was purchased at an average cost of $2.26 per share, with a total value of $33,900.00. Following the acquisition, the director now directly owns 53,315 shares of the company’s stock, valued at approximately $120,491.90. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kelly A. Romano acquired 27,400 shares of Athira Pharma stock in a transaction on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, for a total transaction of $66,308.00. Following the purchase, the director now owns 80,715 shares of the company’s stock, valued at approximately $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ATHA. Perceptive Advisors LLC grew its position in shares of Athira Pharma by 12.6% during the 4th quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock worth $13,129,000 after buying an additional 605,686 shares during the period. Private Advisor Group LLC acquired a new stake in Athira Pharma during the 4th quarter worth $32,000. Clarius Group LLC raised its position in shares of Athira Pharma by 35.8% during the 4th quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock valued at $130,000 after acquiring an additional 14,124 shares during the last quarter. Forefront Analytics LLC lifted its stake in shares of Athira Pharma by 43.0% in the 4th quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after purchasing an additional 8,955 shares during the period. Finally, Mirador Capital Partners LP acquired a new position in shares of Athira Pharma in the 1st quarter valued at $57,000. 57.12% of the stock is currently owned by institutional investors and hedge funds.
Athira Pharma Company Profile
Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.
See Also
- Five stocks we like better than Athira Pharma
- Why Are Stock Sectors Important to Successful Investing?
- Real Estate Stock Signals a Boom in Manufacturing Activity
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- Consumer Staples Stocks, Explained
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.